Seelos therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Seelos therapeutics Contact Number

Contact Seelos

9 hours ago Seelostherapeutics.com Show details

Contact Seelos For inquiries or to request additional information, please email Seelos Therapeutics at [email protected] Please note that Seelos respects the role of healthcare providers in addressing the needs of patients with neurological diseases …

Category: Contact SupportShow more

Seelos Therapeutics, Inc. Company Profile New York, NY

7 hours ago Dnb.com Show details

(646) 998-6475Find company research, competitor information, contact details & financial data for Seelos Therapeutics, Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet.

Employees: 11
Phone: (646) 998-6475
Location: 300 Park Ave FL 12, New York, 10022-7419, NY

Category: Contact NumberShow more

Seelos Therapeutics Crunchbase Company Profile & …

9 hours ago Crunchbase.com Show details

Contact Email [email protected] Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders.

Founded: Jan 01, 2016
Location: New York

Category: Contact NumberShow more

Seelos Therapeutics Overview, News & Competitors

Just Now Zoominfo.com Show details

(646) 998-6475Description. Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medica Read More. Headquarters: 300 Park Ave, New York City, New York, 10022, United States.

Employees: 25
Phone: (646) 998-6475
Location: 300 Park Ave, New York City, 10022

Category: Contact NumberShow more

Seelos Therapeutics, Inc. (SEEL) Fields Kupka & Shukurov LLP

4 hours ago Fksfirm.com Show details

Contact Us INVESTIGATION ALERT: Fields Kupka & Shukurov LLP is investigatin g breach of fiduciary duty cl aims involving the board of directors of Seelos Therapeutics, Inc. (NASDAQ: SEEL). If you are a shareholder of Seelos Therapeutics, Inc. and wish to receive additional information about the investigation and your rights, please fill out and

Category: Contact NumberShow more

Seelos Therapeutics Announces FDA Acceptance of

5 hours ago Prnewswire.com Show details

(646) 293-2136Contact Information Anthony Marciano Chief Communications Officer Seelos Therapeutics, Inc. (Nasdaq: SEEL) 300 Park Avenue New York, NY 10022 (646) 293-2136 [email protected] www

Category: Contact NumberShow more

Seelos Therapeutics Company Profile Office Locations

6 hours ago Craft.co Show details

Seelos Therapeutics has 1.02k Twitter Followers. The number of followers has increased 1.2% month over month and increased 5.9% quarter over quarter

Category: Contact NumberShow more

Seelos Therapeutics Receives Notice of Allowance for an

5 hours ago Seelos.irpass.com Show details

(646) 293-2136Activation of TFEB is an emerging therapeutic target for a number of diseases with pathologic accumulation of storage material. Contact Information: Anthony Marciano Head of Corporate Communications Seelos Therapeutics, Inc. (Nasdaq: SEEL) 300 Park Ave., 12th Fl New York, NY 10022 (646) 293-2136 [email protected] www

Category: Contact NumberShow more

Press Releases

8 hours ago Seelostherapeutics.com Show details

Recent Posts. Panel Replay from Maxim Group LLC and M-Vest’s Advances in Mental Health Virtual Conference on 9/22/2021; Archived webcast from Virtual Cantor Global Healthcare Conference 9/29/2021

Category: Contact NumberShow more

Seelos Therapeutics Announces FDA Acceptance of

8 hours ago Markets.businessinsider.com Show details

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients

Category: Contact NumberShow more

Seelos Therapeutics, Inc. (SEEL) Company Profile

6 hours ago Stockanalysis.com Show details

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal

Category: Contact NumberShow more

Overview and Financials

Just Now Seelostherapeutics.com Show details

Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a responsibly-driven company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases.

Category: Contact NumberShow more

Seelos Therapeutics Inc. (NASDAQ: SEEL) Announce License

3 hours ago Biopharmajournal.com Show details

8 hours ago · Seelos Therapeutics Inc. (NASDAQ: SEEL) and iX BioPharma have announced a license agreement pursuant to which iX Biopharma will license its lead drug candidate under development, Wafermine, and other products that incorporate S- and R- enantiomers of ketamine leveraging WafeiX tech to Seelos. iX Biopharma to receive $9 million advance payment A $9 …

Category: Contact NumberShow more

FORM D SEC

4 hours ago Sec.gov Show details

(646) 998-6475Principal Place of Business and Contact Information. Name of Issuer; SEELOS THERAPEUTICS, INC. Street Address 1 Street Address 2; 300 PARK AVENUE: 12TH FLOOR: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; NEW YORK: NEW YORK: 10017 (646) 998-6475: 3. Related Persons. Last Name c/o Seelos Therapeutics, Inc. 300 …

Category: Contact NumberShow more

Boom Or Bust: What Are Seelos Therapeutics Inc.’s (NASDAQ

7 hours ago Marketingsentinel.com Show details

Seelos Therapeutics Inc. (NASDAQ:SEEL)’s traded shares stood at 4.32 million during the last session, with the company’s beta value hitting 2.75. At the close of trading, the stock’s price was $2.08, to imply a decrease of -4.15% or -$0.09 in intraday trading. The SEEL share’s 52-week high r

Category: Contact NumberShow more

Seelos Therapeutics Announces Issuance of Composition of

4 hours ago Biospace.com Show details

2 days ago · NEW YORK, Dec. 6, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6968839, titled: …

Category: Contact NumberShow more

iX Biopharma inks exclusive agreement with Seelos worth up

9 hours ago Theedgesingapore.com Show details

Pharmaceuticals company iX Biopharma has signed an exclusive license agreement with Seelos Therapeutics for its product, Wafermine. Under terms of the agreement, iX Biopharma will receive an upfront payment of US$9 million ($12 million) to be satisfied in cash and shares. iX Biopharma is also eligible for up to US$239 million in milestone

Category: Contact NumberShow more

SEEL Seelos Therapeutics Inc. • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Show details

About Seelos Therapeutics, Inc. Seelos Therapeutics, Inc. (NASDAQ: SEEL) is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders.

Category: Contact NumberShow more

Seelos Therapeutics Raises $20 Million in Private

2 hours ago Markets.businessinsider.com Show details

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients

Category: Contact NumberShow more

Seelos Therapeutics Number of Employees 20062021 SEEL

6 hours ago Macrotrends.net Show details

Seelos Therapeutics number of employees from 2006 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis

Category: Contact NumberShow more

Seelos Therapeutics to Present a Poster on SLS002

4 hours ago Finance.yahoo.com Show details

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced

Category: Contact NumberShow more

Seelos Therapeutics Raises $20 Million in Private

4 hours ago Ih.advfn.com Show details

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the placement of a $22.0 million senior secured convertible note (the "Note") and shares of Seelos common stock (the …

Category: Contact NumberShow more

Current Report Filing (8k)

1 hours ago Ih.advfn.com Show details

Number : Description: 10.1+* License Agreement, dated as of November 24, 2021, by and between Seelos Therapeutics, Inc. and iX Biopharma Europe Limited: 10.2* Common Stock Purchase Agreement, dated as of November 24, 2021, by and between Seelos Therapeutics, Inc. and iX Biopharma Europe Limited: 99.1 : Press Release, dated November …

Category: Contact NumberShow more

Seelos Therapeutics Announces FDA Acceptance of

6 hours ago Apnews.com Show details

NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted Seelos’ Investigation New Drug (IND) application to …

Category: Contact NumberShow more

Seelos Therapeutics Announces Acquisition of an Exclusive

7 hours ago Advfn.com Show details

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients

Category: Contact NumberShow more

Seelos Therapeutics Presents a Poster on SLS002

6 hours ago Ih.advfn.com Show details

NEW YORK, Oct. 25, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today presented a poster on Part 1, the open-label portion, of the study of SLS-002 (Intranasal Racemic Ketamine) at the IASR/AFSP …

Category: Contact NumberShow more

Seelos Therapeutics Presents a Poster on SLS002 at the

5 hours ago Investingnews.com Show details

Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today presented a poster on

Category: Contact NumberShow more

Seelos Therapeutics Raises $20 Million in Private

3 hours ago Finance.yahoo.com Show details

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced

Category: Contact NumberShow more

Seelos Therapeutics Raises $20 Million in Private

Just Now Wfmz.com Show details

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system

Category: Contact NumberShow more

Seelos Raises $20M, Acquires Ketamine Tech, And Announces

9 hours ago Benzinga.com Show details

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients

Category: Tech SupportShow more

Seelos Therapeutics Inc. (SEEL) Sits On Its Hands At $2.27

3 hours ago Stocksregister.com Show details

Having a second look at Seelos Therapeutics Inc. (NASDAQ:SEEL) provides that stock’s average daily trading volume for 3 months was 3.28 million, while it jumped to 3.76 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 102.23 million.

Category: Contact NumberShow more

SEC FORM D

4 hours ago Sec.gov Show details

(646) 998-6475Principal Place of Business and Contact Information. Name of Issuer; SEELOS THERAPEUTICS, INC. Street Address 1 Street Address 2; 300 PARK AVENUE: 12TH FLOOR: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; NEW YORK: NEW YORK: 10022 (646) 998-6475: 3. Related Persons. Last Name c/o Seelos Therapeutics, Inc. 300 …

Category: Contact NumberShow more

Silo Wellness Announces Corporate Updates Investing News

6 hours ago Investingnews.com Show details

(646) 293-2136Contact Information: Anthony Marciano Chief Communications Officer Seelos Therapeutics, Inc. (Nasdaq: SEEL) 300 Park Avenue, 2 nd Floor New York, NY 10022 (646) 293-2136 [email protected]

Category: Contact NumberShow more

Seelos Therapeutics Funding, Financials, Valuation

8 hours ago Crunchbase.com Show details

Seelos Therapeutics has raised a total of $51.3M in funding over 2 rounds. Their latest funding was raised on Nov 24, 2021 from a Post-IPO Debt round. Seelos Therapeutics is registered under the ticker NASDAQ:SEEL . Seelos Therapeutics is funded by The Lind Partners.

Category: Contact NumberShow more

Seelos Therapeutics to Present at the 4th Annual ALS ONE

4 hours ago Finance.yahoo.com Show details

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced

Category: Contact NumberShow more

Premarket Mover: Seelos Therapeutics Inc (SEEL) Up 4.85%

4 hours ago Investorsobserver.com Show details

Seelos Therapeutics Inc has a Long-Term Technical rank of 43. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 57% of the market scoring higher. In the Biotechnology industry which is number 136 by this metric, SEEL ranks better than 68% of stocks. Important Dates for Investors in SEEL:

Category: Contact NumberShow more

Seelos Therapeutics Completes Acquisition of Trehalose from

7 hours ago Globenewswire.com Show details

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients

Category: Contact NumberShow more

www.sec.gov

8 hours ago Sec.gov Show details

Seelos Therapeutics Announces Senior Management Appointments : NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the promotions of Michael Golembiewski to …

Category: Contact NumberShow more

SEEL Seelos Therapeutics Inc. Company Profile

8 hours ago Wsj.com Show details

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients

Category: Contact NumberShow more

Seelos Therapeutics, Inc. S1 Mar. 30, 2017 4:03 PM

9 hours ago Seekingalpha.com Show details

Seelos Therapeutics, Inc. (SEEL) An increase of shares in the number of shares offered by us would increase our as adjusted net tangible book value by …

Category: Contact NumberShow more

Seelos Therapeutics to Present at the 4th Annual ALS ONE

8 hours ago Biospace.com Show details

NEW YORK, Nov. 10, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present at the 4 th Annual ALS ONE Research Symposium, November 29-30 th, 2021.

Category: Contact NumberShow more

Seelos Therapeutics gets Japenese patent covering

8 hours ago Pharmabiz.com Show details

5 hours ago · Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for CNS disorders and rare diseases, announced that it has received an issued patent from the Japanese patent office (Japanese patent number 6968839, titled: Structure-Based Peptide

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Popular Brands

Sharp
Shell
Sap
Sgs
Sabb
Sea